Fabiana Colucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabiana Colucci has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
Mariachiara Sensi
Department of Neurosciences, Arcispedale Sant'Anna Hospital, Ferrara, Italy
9 shared publications- Roberto Eleopra
Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milano, Italy
9 shared publications - Luigi Michele Romito
Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
8 shared publications Maura Pugliatti
Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy
7 shared publicationsAndrea Gozzi
Department of Neurosciences, Arcispedale Sant'Anna Hospital, Ferrara, Italy
6 shared publications- Antonio Emanuele Elia
Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
6 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson’s disease
Bilateral subthalamic nucleus Deep Brain Stimulation (STN-DBS) and Levodopa-Carbidopa Intestinal Gel (LCIG) represent established treatment options for complicated Parkinson's disease (PD). Evidence regarding their effectiveness on axial symptoms remains limited, despite disability. This observational real-world cohort study included 317 PD patients who received STN-DBS (N = 203) or LCIG (N = 114) between 2005 and 2023 at two Italian centeres to compare their short- and long-term effects on axial symptoms. At baseline, LCIG group exhibited more severe axial and motor symptoms and higher prevalence of cognitive abnormalities than STN-DBS cohort. Longitudinally, LCIG treatment was associated with lower odds of long-term axial deterioration compared with STN-DBS, after adjustment for baseline differences and levodopa equivalent daily dose, despite an increased risk of dyskinesias. A significant treatment-by-time interaction suggested more favourable long-term axial symptom trajectories in the LCIG group.
- 14 July 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessSTN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson’s disease
Bilateral subthalamic nucleus Deep Brain Stimulation (STN-DBS) and Levodopa-Carbidopa Intestinal Gel (LCIG) represent established treatment options for complicated Parkinson's disease (PD). Evidence regarding their effectiveness on axial symptoms remains limited, despite disability. This observational real-world cohort study included 317 PD patients who received STN-DBS (N = 203) or LCIG (N = 114) between 2005 and 2023 at two Italian centeres to compare their short- and long-term effects on axial symptoms. At baseline, LCIG group exhibited more severe axial and motor symptoms and higher prevalence of cognitive abnormalities than STN-DBS cohort. Longitudinally, LCIG treatment was associated with lower odds of long-term axial deterioration compared with STN-DBS, after adjustment for baseline differences and levodopa equivalent daily dose, despite an increased risk of dyskinesias. A significant treatment-by-time interaction suggested more favourable long-term axial symptom trajectories in the LCIG group.
- Open Access
- 13 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1918-1925
Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease
Background: Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives: To identify key factors to improve decision‐making in DBS management for LSPD patients. Methods: We retrospectively analyzed demographic, clinical and stimulation parameters in LSPD patients (Hoehn and Yahr ≥4; Schwab and England ≤50) who either maintained best medical therapy (BMT) or required unscheduled device‐aided therapy (DAT) implantation up to 1 year after DBS discontinuation. Results: From 2005 to 2022, 94 patients with bilateral subthalamic nucleus DBS were reviewed and among the 31 patients who have transitioned to LSPD, 15 patients remained on BMT, while 10 required rescue DAT (6 unscheduled implantable pulse generator replacements and 4 Levodopa‐Carbidopa Intestinal Gel) within 3 months after discontinuation. Significant differences were observed in years of DBS (12.4 vs. 8.5), modified Falls Efficacy Scale (12.5 vs. 21.2), and months since the last parameter adjustment (30.3 vs. 23.2), with a trend toward less ΔMDS‐UPDRS III worsening after stimulation was switched off (7.6 vs. 10.9). Longer DBS duration was inversely associated with rescue DAT (OR 0.529; 95% CI, 0.284–0.986), with a cutoff of 10.5 years. Conclusion: In selected LSPD patients, a transition from DBS to BMT alone can be attempted with long‐term stability, whereas in others a more conservative approach is advisable, and stimulation should be continued. Clinical, therapeutic, and care‐related factors should guide decisions when discontinuation is being considered.
- 13 February 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (8) , 1918-1925
Open AccessRisk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease
Background: Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives: To identify key factors to improve decision‐making in DBS management for LSPD patients. Methods: We retrospectively analyzed demographic, clinical and stimulation parameters in LSPD patients (Hoehn and Yahr ≥4; Schwab and England ≤50) who either maintained best medical therapy (BMT) or required unscheduled device‐aided therapy (DAT) implantation up to 1 year after DBS discontinuation. Results: From 2005 to 2022, 94 patients with bilateral subthalamic nucleus DBS were reviewed and among the 31 patients who have transitioned to LSPD, 15 patients remained on BMT, while 10 required rescue DAT (6 unscheduled implantable pulse generator replacements and 4 Levodopa‐Carbidopa Intestinal Gel) within 3 months after discontinuation. Significant differences were observed in years of DBS (12.4 vs. 8.5), modified Falls Efficacy Scale (12.5 vs. 21.2), and months since the last parameter adjustment (30.3 vs. 23.2), with a trend toward less ΔMDS‐UPDRS III worsening after stimulation was switched off (7.6 vs. 10.9). Longer DBS duration was inversely associated with rescue DAT (OR 0.529; 95% CI, 0.284–0.986), with a cutoff of 10.5 years. Conclusion: In selected LSPD patients, a transition from DBS to BMT alone can be attempted with long‐term stability, whereas in others a more conservative approach is advisable, and stimulation should be continued. Clinical, therapeutic, and care‐related factors should guide decisions when discontinuation is being considered.
- Open Access
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214036
Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant
Deep brain stimulation (DBS) is an established treatment for Parkinson disease (PD). In patients carrying GBA1 variants (GBA-PD), concerns persist that DBS may accelerate cognitive decline. This study investigated the potential additive effects of GBA1 genotype and DBS on long-term motor and nonmotor outcomes. This multicenter retrospective, controlled, Italian study included 3 groups: DBS-treated PD patients either carrying or noncarrying GBA1 variants (DBS-nonGBA-PD and DBS-GBA-PD) and GBA-PD patients who fulfilled DBS criteria but eventually were not operated. As secondary aims, we assessed the clinical outcomes of DBS-GBA-PD stratified by GBA1 variant classes and by different DBS targets. Cognitive, motor, and other nonmotor features were collected at baseline and after 1, 3 and, when available, 5 years. Between-group comparisons used χ2 and Kruskal-Wallis tests with Bonferroni correction. Longitudinal changes were analyzed with linear mixed-effects models. Subgroup analyses were performed by GBA1 variant class and DBS target. A total of 615 participants were included: 430 DBS-nonGBA-PD (age 57.4 ± 7.7 years, 32% female), 109 DBS-GBA-PD (age 53.5 ± 8.4 years, 38% female), and 76 nonDBS-GBA-PD (age 57.7 ± 8.1 years, 37% female). At baseline, groups were largely matched for clinical features. Longitudinally, both DBS groups showed marked motor improvement (dyskinesias, on-off phenomenon, and wearing-off, all p vs T0 < 0.001), a benefit which was absent in nonDBS-GBA-PD. At 5 years, dementia occurred more frequently in DBS-GBA-PD and nonDBS-GBA-PD compared with DBS-nonGBA-PD (25.5% vs 36.8% vs 10.8%, p < 0.001). Hallucinations and urinary problems increased in both GBA-PD groups than nonGBA-PD (p-between GBA1-associated PD.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214036
Open AccessLong-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant
Deep brain stimulation (DBS) is an established treatment for Parkinson disease (PD). In patients carrying GBA1 variants (GBA-PD), concerns persist that DBS may accelerate cognitive decline. This study investigated the potential additive effects of GBA1 genotype and DBS on long-term motor and nonmotor outcomes. This multicenter retrospective, controlled, Italian study included 3 groups: DBS-treated PD patients either carrying or noncarrying GBA1 variants (DBS-nonGBA-PD and DBS-GBA-PD) and GBA-PD patients who fulfilled DBS criteria but eventually were not operated. As secondary aims, we assessed the clinical outcomes of DBS-GBA-PD stratified by GBA1 variant classes and by different DBS targets. Cognitive, motor, and other nonmotor features were collected at baseline and after 1, 3 and, when available, 5 years. Between-group comparisons used χ2 and Kruskal-Wallis tests with Bonferroni correction. Longitudinal changes were analyzed with linear mixed-effects models. Subgroup analyses were performed by GBA1 variant class and DBS target. A total of 615 participants were included: 430 DBS-nonGBA-PD (age 57.4 ± 7.7 years, 32% female), 109 DBS-GBA-PD (age 53.5 ± 8.4 years, 38% female), and 76 nonDBS-GBA-PD (age 57.7 ± 8.1 years, 37% female). At baseline, groups were largely matched for clinical features. Longitudinally, both DBS groups showed marked motor improvement (dyskinesias, on-off phenomenon, and wearing-off, all p vs T0 < 0.001), a benefit which was absent in nonDBS-GBA-PD. At 5 years, dementia occurred more frequently in DBS-GBA-PD and nonDBS-GBA-PD compared with DBS-nonGBA-PD (25.5% vs 36.8% vs 10.8%, p < 0.001). Hallucinations and urinary problems increased in both GBA-PD groups than nonGBA-PD (p-between GBA1-associated PD.
- Open Access
- 3 September 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (5) , 1
Correction to: Sex Differences in Spinocerebellar Ataxia Type 1: Clinical Presentation and Progression
- 3 September 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (5) , 1
Open AccessCorrection to: Sex Differences in Spinocerebellar Ataxia Type 1: Clinical Presentation and Progression
- Open Access
- 15 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 2034-2042
Opicapone in Parkinson's Disease on Levodopa‐Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study
Background: Levodopa‐carbidopa intestinal gel infusion (LCIG) is an effective therapy for advanced Parkinson's disease (PD). Opicapone (OPC) is an enzyme inhibitor that enhances the bioavailability of levodopa in the brain. Objectives: This study evaluates the effect of Opicapone addition in PD‐LCIG patients, assessing its impact on motor fluctuations and dyskinesias. Secondly, the study analyses the impact of OPC on non‐motor symptoms, LCIG dosage, and peripheral neuropathy. Methods: In this pilot study, 22 PD patients on LCIG were randomized to receive OPC or not, based on persistent or reemergent fluctuations. The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), Unified Dyskinesia Rating Scale (UDysRS), Montreal Cognitive Assessment (MoCA), electroneurography (ENG), LCIG doses, homocysteine, vitamin B12, and folic acid levels were measured at baseline (T0) and after 12 months (T1). Results: Eleven patients added OPC (addOPC group), while 11 maintained standard treatment (nOPC group). At baseline, both groups had similar disease duration and severity. At T1, the addOPC group showed significant: (i) improvement in motor fluctuations evaluated by the MDS‐UPDRS part IV; (ii) reduction in dyskinesias (UDyRS); (iii) decrease in LCIG infusion rate; (iv) improvement in motor and non‐motor symptoms (MDS‐UPDRS parts I‐III); (v) increase in Vitamin B12. No significant differences were observed in the ENG data, and no serious adverse events occurred. Four addOPC patients (36%) discontinued OPC after 15 ± 2 months, mainly due to hallucinations. Conclusions: OPC addition appeared well tolerated and beneficial in reducing motor fluctuations, dyskinesia, and LCIG dose. Randomized controlled trials are needed to confirm these findings.
- 15 July 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 2034-2042
Open AccessOpicapone in Parkinson's Disease on Levodopa‐Carbidopa Intestinal Gel Treatment: A Pilot, Randomized Study
Background: Levodopa‐carbidopa intestinal gel infusion (LCIG) is an effective therapy for advanced Parkinson's disease (PD). Opicapone (OPC) is an enzyme inhibitor that enhances the bioavailability of levodopa in the brain. Objectives: This study evaluates the effect of Opicapone addition in PD‐LCIG patients, assessing its impact on motor fluctuations and dyskinesias. Secondly, the study analyses the impact of OPC on non‐motor symptoms, LCIG dosage, and peripheral neuropathy. Methods: In this pilot study, 22 PD patients on LCIG were randomized to receive OPC or not, based on persistent or reemergent fluctuations. The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), Unified Dyskinesia Rating Scale (UDysRS), Montreal Cognitive Assessment (MoCA), electroneurography (ENG), LCIG doses, homocysteine, vitamin B12, and folic acid levels were measured at baseline (T0) and after 12 months (T1). Results: Eleven patients added OPC (addOPC group), while 11 maintained standard treatment (nOPC group). At baseline, both groups had similar disease duration and severity. At T1, the addOPC group showed significant: (i) improvement in motor fluctuations evaluated by the MDS‐UPDRS part IV; (ii) reduction in dyskinesias (UDyRS); (iii) decrease in LCIG infusion rate; (iv) improvement in motor and non‐motor symptoms (MDS‐UPDRS parts I‐III); (v) increase in Vitamin B12. No significant differences were observed in the ENG data, and no serious adverse events occurred. Four addOPC patients (36%) discontinued OPC after 15 ± 2 months, mainly due to hallucinations. Conclusions: OPC addition appeared well tolerated and beneficial in reducing motor fluctuations, dyskinesia, and LCIG dose. Randomized controlled trials are needed to confirm these findings.
- Open Access
- 10 July 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (5) , 1-11
Sex Differences in Spinocerebellar Ataxia Type 1: Clinical Presentation and Progression
Background: Spinocerebellar ataxia type 1 (SCA1) is characterised by motor and cognitive symptoms. Sex-specific differences in disease presentation and progression remain poorly understood. This study investigates the role of sex in clinical-demographic and motor/cognitive outcomes in SCA1. Methods: This single-centre, longitudinal observational cohort study was conducted at the University Hospital of Ferrara between 2021 and 2024. Consecutively, genetically confirmed SCA1 patients were evaluated at baseline and after 24±6 months. Assessments included comprehensive neuropsychological testing and auditory event-related potentials (aERPs). Motor function was evaluated using the Scale for Assessment and Rating of Ataxia (SARA). Results: Sixteen SCA1 patients (9 males, seven females) were evaluated at baseline, with 10 patients (5 males, five females) completing follow-up. Even if most cognitive functions were preserved in both sexes at baseline, males showed worse performance in emotion attribution tasks than females (42.8 ± 8.5 vs. 53.1 ± 5.7, r = 0.63). Over time, both sexes showed slightly worsening cognitive performance, although not statistically significant, with males demonstrating deficits in verbal fluency (p = 0.036) and emotion attribution (p = 0.048). In the same group, motor impairment worsened at follow-up, though not significantly. aERPs revealed no differences between sexes at follow-up. Conclusion: Sex may influence cognitive outcomes in SCA1, with male patients showing greater vulnerability to cognitive decline. aERPs did not show significant modifications. These findings highlight the importance of considering sex-specific approaches in the clinical management of SCA1 patients and the higher values of a comprehensive neuropsychological assessment compared to the neurophysiological approach with aERPs to reach these slight changes over time. Clinical trial number: Not applicable.
- 10 July 2025
- Published by Springer Nature in The Cerebellum
- Vol. 24 (5) , 1-11
Open AccessSex Differences in Spinocerebellar Ataxia Type 1: Clinical Presentation and Progression
Background: Spinocerebellar ataxia type 1 (SCA1) is characterised by motor and cognitive symptoms. Sex-specific differences in disease presentation and progression remain poorly understood. This study investigates the role of sex in clinical-demographic and motor/cognitive outcomes in SCA1. Methods: This single-centre, longitudinal observational cohort study was conducted at the University Hospital of Ferrara between 2021 and 2024. Consecutively, genetically confirmed SCA1 patients were evaluated at baseline and after 24±6 months. Assessments included comprehensive neuropsychological testing and auditory event-related potentials (aERPs). Motor function was evaluated using the Scale for Assessment and Rating of Ataxia (SARA). Results: Sixteen SCA1 patients (9 males, seven females) were evaluated at baseline, with 10 patients (5 males, five females) completing follow-up. Even if most cognitive functions were preserved in both sexes at baseline, males showed worse performance in emotion attribution tasks than females (42.8 ± 8.5 vs. 53.1 ± 5.7, r = 0.63). Over time, both sexes showed slightly worsening cognitive performance, although not statistically significant, with males demonstrating deficits in verbal fluency (p = 0.036) and emotion attribution (p = 0.048). In the same group, motor impairment worsened at follow-up, though not significantly. aERPs revealed no differences between sexes at follow-up. Conclusion: Sex may influence cognitive outcomes in SCA1, with male patients showing greater vulnerability to cognitive decline. aERPs did not show significant modifications. These findings highlight the importance of considering sex-specific approaches in the clinical management of SCA1 patients and the higher values of a comprehensive neuropsychological assessment compared to the neurophysiological approach with aERPs to reach these slight changes over time. Clinical trial number: Not applicable.
- Open Access
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6094
LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients
Heterozygous mutations in the GBA1 gene, encoding the enzyme glucocerebrosidase (GCase), are major risk factors for Parkinson’s Disease (PD). Ambroxol, a small chaperone originally used as a mucolytic agent, has been shown to cross the blood–brain barrier, enhance GCase activity, and reduce α-synuclein levels, making it a promising therapeutic candidate for disease-modifying effects in GBA1-associated PD (GBA1-PD). This study aimed to develop a method to quantify ambroxol levels in human plasma and cerebrospinal fluid (CSF) using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Ambroxol was determined by online solid-phase extraction (SPE), coupled with LC-MS/MS, by gradient elution on a monolithic column. Detection employed a 3200 QTRAP tandem mass spectrometer in the positive electrospray ionization mode. Calibration curves exhibited linearity across the analyzed ranges in both plasma and CSF. The recovery rate ranged from 106.7% to 113.5% in plasma and from 99.0% to 103.0% in CSF. No significant matrix effect was observed. Intra-day and inter-day precisions were below 11.8% in both matrices, and accuracy ranged from 89.9% to 103.1% in plasma and from 96.3% to 107.8% in CSF. We evaluated and confirmed the stability of the analyte in plasma and CSF across various storage conditions. The method was successfully validated according to European Medicine Agency (EMA) guidelines and its applicability was confirmed in the context of a multicenter, randomized, double-blind, placebo-controlled, phase II study, designed to monitor the ambroxol levels in the plasma and CSF of GBA1-PD.
- 25 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6094
Open AccessLC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients
Heterozygous mutations in the GBA1 gene, encoding the enzyme glucocerebrosidase (GCase), are major risk factors for Parkinson’s Disease (PD). Ambroxol, a small chaperone originally used as a mucolytic agent, has been shown to cross the blood–brain barrier, enhance GCase activity, and reduce α-synuclein levels, making it a promising therapeutic candidate for disease-modifying effects in GBA1-associated PD (GBA1-PD). This study aimed to develop a method to quantify ambroxol levels in human plasma and cerebrospinal fluid (CSF) using liquid chromatography–tandem mass spectrometry (LC-MS/MS). Ambroxol was determined by online solid-phase extraction (SPE), coupled with LC-MS/MS, by gradient elution on a monolithic column. Detection employed a 3200 QTRAP tandem mass spectrometer in the positive electrospray ionization mode. Calibration curves exhibited linearity across the analyzed ranges in both plasma and CSF. The recovery rate ranged from 106.7% to 113.5% in plasma and from 99.0% to 103.0% in CSF. No significant matrix effect was observed. Intra-day and inter-day precisions were below 11.8% in both matrices, and accuracy ranged from 89.9% to 103.1% in plasma and from 96.3% to 107.8% in CSF. We evaluated and confirmed the stability of the analyte in plasma and CSF across various storage conditions. The method was successfully validated according to European Medicine Agency (EMA) guidelines and its applicability was confirmed in the context of a multicenter, randomized, double-blind, placebo-controlled, phase II study, designed to monitor the ambroxol levels in the plasma and CSF of GBA1-PD.
- Open Access
- 30 January 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (5) , 826-844
Spiking Patterns in the Globus Pallidus Highlight Convergent Neural Dynamics across Diverse Genetic Dystonia Syndromes
Objective: Genetic dystonia is a complex movement disorder with diverse clinical manifestations resulting from pathogenic mutations in associated genes. A recent paradigm shift emphasizes the functional convergence among dystonia genes, hinting at a shared pathomechanism. However, the neural dynamics supporting this convergence remain largely unexplored.Methods: Herein, we analyzed microelectrode recordings acquired during pallidal deep brain stimulation surgery from 31 dystonia patients with pathogenic mutations in the AOPEP, GNAL, KMT2B, PANK2, PLA2G6, SGCE, THAP1, TOR1A, and VPS16 genes. We identified 1,694 single units whose activity was characterized by a broad set of neural features.Results: AOPEP, PANK2, and THAP1 displayed higher firing regularity, whereas GNAL, PLA2G6, KMT2B, and SGCE shared a large fraction of bursting neurons (> 26.6%), significantly exceeding the rate in other genes. TOR1A and VPS16 genes constituted an intermediate group, bridging these 2 groups, due to having the highest degree of spiking irregularity. Hierarchical clustering algorithms based on these dynamics confirmed the results obtained with first‐order comparisons.Interpretation: Despite lacking common molecular pathways, dystonia genes share largely overlapping structures of neural patterns, in particular the degree of pallidal spiking regularity and bursting activity. We propose that the degree of desynchronization facilitated by pallidal neural bursts may explain the variability in deep brain stimulation (DBS) of the globus pallidus internus (GPi) surgery outcomes across genetic dystonia syndromes. Lastly, investigating the effects of genetic mutations on low‐frequency pallidal activity could optimize personalized adaptive DBS treatments in patients with genetic dystonia. ANN NEUROL 2025;97:826–844
- 30 January 2025
- Published by Wiley in Annals of Neurology
- Vol. 97 (5) , 826-844
Open AccessSpiking Patterns in the Globus Pallidus Highlight Convergent Neural Dynamics across Diverse Genetic Dystonia Syndromes
Objective: Genetic dystonia is a complex movement disorder with diverse clinical manifestations resulting from pathogenic mutations in associated genes. A recent paradigm shift emphasizes the functional convergence among dystonia genes, hinting at a shared pathomechanism. However, the neural dynamics supporting this convergence remain largely unexplored.Methods: Herein, we analyzed microelectrode recordings acquired during pallidal deep brain stimulation surgery from 31 dystonia patients with pathogenic mutations in the AOPEP, GNAL, KMT2B, PANK2, PLA2G6, SGCE, THAP1, TOR1A, and VPS16 genes. We identified 1,694 single units whose activity was characterized by a broad set of neural features.Results: AOPEP, PANK2, and THAP1 displayed higher firing regularity, whereas GNAL, PLA2G6, KMT2B, and SGCE shared a large fraction of bursting neurons (> 26.6%), significantly exceeding the rate in other genes. TOR1A and VPS16 genes constituted an intermediate group, bridging these 2 groups, due to having the highest degree of spiking irregularity. Hierarchical clustering algorithms based on these dynamics confirmed the results obtained with first‐order comparisons.Interpretation: Despite lacking common molecular pathways, dystonia genes share largely overlapping structures of neural patterns, in particular the degree of pallidal spiking regularity and bursting activity. We propose that the degree of desynchronization facilitated by pallidal neural bursts may explain the variability in deep brain stimulation (DBS) of the globus pallidus internus (GPi) surgery outcomes across genetic dystonia syndromes. Lastly, investigating the effects of genetic mutations on low‐frequency pallidal activity could optimize personalized adaptive DBS treatments in patients with genetic dystonia. ANN NEUROL 2025;97:826–844
- Open Access
- 18 January 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (3) , 478-489
Magnetic Resonance–Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy of ventral intermediate (Vim) nucleus is useful to treat drug‐resistant tremor‐dominant Parkinson's disease (TdPD), but tremor relapse may occur. Predictors of relapse have been poorly investigated so far.Objective: The aim of this study is to evaluate the role of clinico‐demographic, procedural, and neuroradiological variables in determining clinical response, relapse, and adverse events (AEs) in TdPD after MRgFUS Vim‐thalamotomy.Methods: Fifty‐two TdPD patients who consecutively underwent unilateral MRgFUS Vim‐thalamotomy were prospectively evaluated at baseline and after 24 hours, 1 month, 6 months, and 12 months using MDS‐UPDRS‐III in off and on medication conditions. AEs were collected at each evaluation. Lesion volume was calculated at 24‐hour magnetic resonance imaging (MRI). Patients with tremor improvement 30% at 24 hours. Tremor relapse occurred in 12 patients (23%), exclusively during the first month after thalamotomy. Relapse was associated with younger age (P = 0.030) and smaller lesion volume (P = 0.030). At 1 month, 22 patients (42%) had AEs; at 6 and 12 months, AEs persisted in 19% and 6% of cases. AEs at 6 months were associated with larger lesions (P = 0.018). All AEs were mild.Conclusions: MRgFUS Vim‐thalamotomy is effective in treating tremor in TdPD. Relapse is associated with younger age and smaller lesion volume, but larger lesions make AEs more likely to persist. We suggest that a lesion volume between 145 and 220 mm3 on T1‐weighted MRI may be the therapeutic window that ensures tremor control without long‐lasting AEs. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 18 January 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (3) , 478-489
Open AccessMagnetic Resonance–Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy of ventral intermediate (Vim) nucleus is useful to treat drug‐resistant tremor‐dominant Parkinson's disease (TdPD), but tremor relapse may occur. Predictors of relapse have been poorly investigated so far.Objective: The aim of this study is to evaluate the role of clinico‐demographic, procedural, and neuroradiological variables in determining clinical response, relapse, and adverse events (AEs) in TdPD after MRgFUS Vim‐thalamotomy.Methods: Fifty‐two TdPD patients who consecutively underwent unilateral MRgFUS Vim‐thalamotomy were prospectively evaluated at baseline and after 24 hours, 1 month, 6 months, and 12 months using MDS‐UPDRS‐III in off and on medication conditions. AEs were collected at each evaluation. Lesion volume was calculated at 24‐hour magnetic resonance imaging (MRI). Patients with tremor improvement 30% at 24 hours. Tremor relapse occurred in 12 patients (23%), exclusively during the first month after thalamotomy. Relapse was associated with younger age (P = 0.030) and smaller lesion volume (P = 0.030). At 1 month, 22 patients (42%) had AEs; at 6 and 12 months, AEs persisted in 19% and 6% of cases. AEs at 6 months were associated with larger lesions (P = 0.018). All AEs were mild.Conclusions: MRgFUS Vim‐thalamotomy is effective in treating tremor in TdPD. Relapse is associated with younger age and smaller lesion volume, but larger lesions make AEs more likely to persist. We suggest that a lesion volume between 145 and 220 mm3 on T1‐weighted MRI may be the therapeutic window that ensures tremor control without long‐lasting AEs. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Rechargeable and Nonrechargeable Implantable Pulse Generators for Deep Brain Stimulation in Parkinson’s Disease: Long‐Term Experience
Objectives: The study’s objective is to assess long‐term experience with rechargeable (r‐IPG) and nonrechargeable implant pulse generators (nr‐IPGs) for deep brain stimulation (DBS) in Parkinson’s disease (PD). Material and Methods: Qualitative semistructured interviews, clinical outcomes, and care load estimations were retrospectively collected for a PD‐DBS population implanted at our center from 2006 to 2022. Results: Thirty‐seven nr‐IPG patients (follow‐up 85.3 ± 32.0 months) and 43 r‐IPG patients (follow‐up 73.1 ± 7.7 months) were analyzed. Long‐term satisfaction was sustained in both groups (100% of r‐IPG carriers and 75.7% of nr‐IPGs, p = 0.001). In r‐IPGs, 97.7% recharged the battery easily, and recharging time did not impact everyday life. The percentage of malfunctioning problems (32.6%) in the r‐IPG group was in line with previous observations on short‐term follow‐ups. The size of the IPG was considered too big for 16.2% and 4.2% for nr‐IPGs and r‐IPGs ( p = 0.086), and concerns of interventions for IPG replacements were still present in the nr‐IPG group (48.6%). The total amount of days of hospitalization (19.6 ± 9.9 vs. 9.3 ± 4.8, p < 0.001) and the number of complications after the first implant (13 vs. 5, p < 0.05) and during subsequent admissions for IPG substitutions (4 vs. 0, p < 0.05) were higher for the nr‐IPGs. Conclusions: The overall level of long‐term satisfaction with IPGs is consistent over time regardless of type. R‐IPGs reported no discomfort with recharging even in the long‐term evaluation. IPG replacement surgeries and sizes are still a concern, especially for the nr‐IPG carriers, but did not affect a high level of sustained satisfaction. Resource burden remains higher for nr‐IPGs even in the long term.
- 1 January 2025
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2025 (1)
Open AccessRechargeable and Nonrechargeable Implantable Pulse Generators for Deep Brain Stimulation in Parkinson’s Disease: Long‐Term Experience
Objectives: The study’s objective is to assess long‐term experience with rechargeable (r‐IPG) and nonrechargeable implant pulse generators (nr‐IPGs) for deep brain stimulation (DBS) in Parkinson’s disease (PD). Material and Methods: Qualitative semistructured interviews, clinical outcomes, and care load estimations were retrospectively collected for a PD‐DBS population implanted at our center from 2006 to 2022. Results: Thirty‐seven nr‐IPG patients (follow‐up 85.3 ± 32.0 months) and 43 r‐IPG patients (follow‐up 73.1 ± 7.7 months) were analyzed. Long‐term satisfaction was sustained in both groups (100% of r‐IPG carriers and 75.7% of nr‐IPGs, p = 0.001). In r‐IPGs, 97.7% recharged the battery easily, and recharging time did not impact everyday life. The percentage of malfunctioning problems (32.6%) in the r‐IPG group was in line with previous observations on short‐term follow‐ups. The size of the IPG was considered too big for 16.2% and 4.2% for nr‐IPGs and r‐IPGs ( p = 0.086), and concerns of interventions for IPG replacements were still present in the nr‐IPG group (48.6%). The total amount of days of hospitalization (19.6 ± 9.9 vs. 9.3 ± 4.8, p < 0.001) and the number of complications after the first implant (13 vs. 5, p < 0.05) and during subsequent admissions for IPG substitutions (4 vs. 0, p < 0.05) were higher for the nr‐IPGs. Conclusions: The overall level of long‐term satisfaction with IPGs is consistent over time regardless of type. R‐IPGs reported no discomfort with recharging even in the long‐term evaluation. IPG replacement surgeries and sizes are still a concern, especially for the nr‐IPG carriers, but did not affect a high level of sustained satisfaction. Resource burden remains higher for nr‐IPGs even in the long term.